PureTech Health (LON:PRTC) Shares Up 14.2% - Here's Why

Key Points

• PureTech Health's stock price surged by 14.2% on the latest trading day, closing at GBX 121.50 ($1.65) after reaching a high of GBX 123.80 ($1.68).
• Insider Bharatt Chowrira purchased 167,739 shares of the company's stock at a total value of £1,677.39, indicating insider confidence.
• The company has a market capitalization of £293.65 million and is engaged in developing medicines targeting issues in the nervous, gastrointestinal, and immune systems.

PureTech Health plc (LON:PRTC - Get Free Report) shot up 14.2% during trading on Friday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). 9,013,305 shares changed hands during trading, an increase of 1,053% from the average session volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Stock Up 4.2%

The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82. The firm has a market cap of £303.07 million, a price-to-earnings ratio of 737.65 and a beta of 1.02. The stock's 50 day moving average is GBX 129.31 and its 200 day moving average is GBX 129.65.

Insider Activity at PureTech Health

In related news, insider Bharatt Chowrira acquired 167,739 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were acquired at an average price of GBX 1 per share, for a total transaction of £1,677.39. 13.13% of the stock is owned by corporate insiders.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.